B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
Event / China / Regulatory Affairs
China Regulatory Workshop
November 19, 2024 | 11:30 AM – 6:30 PM PT November 20, 2024 | 8:15 AM – 4:00 PM PT
Get the latest on new policy updates and guidance for the clinical evaluation of medical devices.
Event / Regulatory Affairs
Medical Device Submissions Workshops – 510(k) and De Novo
510(k) and De Novo Submissions Workshop: February 3-4, 2025
IDE Submissions Workshop: February 5, 2025
PMA Submissions Workshop: February 6-7, 2025
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.
News / Regulatory Affairs
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
July 31, 2024
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Event / Digital Health / Regulatory Affairs
AdvaMed Cybersecurity Summit
November 13, 2024
8:15 AM – 6:00 PM
Join us in Washington, D.C. for our Cybersecurity Summit that will address the future of medical device cybersecurity and changes in the industry landscape related to FDA requirements.
Resource / Regulatory Affairs
MedTech Reimbursement Playbook
July 17, 2024
Learn the basic principles of how medical technologies are covered and paid by insurers and the challenges medtech companies face.
News / Global & Trade
AdvaMed Signs New MOU with British Medtech Association
June 26, 2024
AdvaMed, the Medtech Association, signed a renewed memorandum of understanding with the Association of British HealthTech Industries (ABHI) to strengthen the relationship between two of the leading medtech organizations in the world.
News / Global & Trade
AdvaMed Statement on FDA-USAID India Regulatory Session
April 16, 2024
AdvaMed, the Medtech Association, released the following statement thanking the FDA Center for Radiological Health (CDRH) for recently hosting an event in New Delhi to discuss regulatory policies and best practices for ensuring medical technology reaches patients. The event, called “Minds to Markets: Regulatory Considerations in Med-Tech,” advances US-India cooperation on medtech supply chain through greater regulatory alignment.
Resource / Regulatory Affairs
Successful Market Access of SaMD & MDSW: Decoding the Confusion in MedTech Software Development
April 12, 2024
Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.